5-乙基-2-甲氧基-3-甲基吡嗪 | 93034-73-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-乙基-2-甲氧基-3-甲基吡嗪
• 英文名称: 5-Ethyl-2-methoxy-3-methylpyrazine
• CAS: 93034-73-2
• 化学式: C₈H₁₂N₂O
• 分子量: 152.19
• InChiKey: KTGLSFZUDOBUIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Pyrazole N-Linked Carbamoyl Cyclohexyl Acids as LPA Antagonists
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20210087173A1

  公开（公告）日：2021-03-25

  The present invention provides compounds of Formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein X 1 , X 2 , X 3 , and X 4 are each independently CR 6 or N; provided that no more than two of X 1 , X 2 , X 3 , or X 4 are N; Q 2 is N or NR 5a ; one of Q 1 and Q 3 is CR 5 , and the other is N or NR 5a ; and the dashed circle denotes optional bonds forming an aromatic ring; Y 1 is O or NR 3 ; Y 2 is —CO—, —SO 2 —, or —S(O(NH)—; Y 3 is O or NR 4 a; provided that (1) Y 1 and Y 3 are not both O, and (2) when Y 2 is C(O), Y 1 is not O; L is a covalent bond or C 1-4 alkylene substituted with 0 to 4 R 7 ; R 1 is (—CH 2 ) a R 9 ; a is an integer of 0 or 1; R 2 is each independently halo, cyano, hydroxyl, amino, C 1-6 alkyl, C 3-6 cycloalkyl, C 4-6 heterocyclyl, alkylamino, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxy, alkoxyalkyl, haloalkoxyalkyl, or haloalkoxy; n is an integer of 0, 1, or 2; R 3 and R 4a are independently hydrogen, C 1-6 alkyl, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; R 4 is C 1-10 alkyl, C 1-10 haloalkyi, C 1-10 deuterated alkyl, C 1-10 alkenyl, C 3-8 cycloalkyl, 6 to 10-membered aryl, 3 to 8-membered heterocyclyl, —(Ci-6 alkylene)-(C3-8 cycloalkyl), —(C 1-6 alkylene)-(6 to 10-membered aryl), —(C 1-6 alkylene)-(3 to 8-membered heterocyclyl), or —(C 1-6 alkylene)-(5 to 6-membered heteroaryl); wherein each of the alkyl, alkylene, alkenyl, cycloalkyl, aryl, heterocyclyl, and heteroaryl, by itself or as part of other moiety, is independently substituted with 0 to 3 R; or alternatively, R 3 and R 4 , taken together with the N and 0 atoms which they are attached, form a 4 to 9-membered heterocyclic ring moiety which is substituted with 0 to 3 R 8 ; or alternatively, (R 3 and R 5a ) or (R 3 and R 5 ), taken together with the atoms to which they are attached to, form a 5 to 8-membered heterocyclic ring moiety which is substituted with 0 to 3 R 8 ; R 5a is hydrogen, C 1-6 alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; R 5 and R 6 are each independently hydrogen, halo, cyano, hydroxyl, amino, alkyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; R 7 is halo, oxo, cyano, hydroxyl, amino, C 1-6 alkyl, C 3-6 cycloalkyl, C 4-6 heterocyclyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, or haloalkoxy; R 8 are each independently deuterium, halo, hydroxyl, amino, cyano, C 1-6 alkyl, C 1-6 deuterated alkyl, C 2-6 alkenyl, C 2-6 alkynyl, alkylamino, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, haloalkoxy, phenyl, or 5 to 6-membered heteroaryl; or alternatively, two R 8 , taken together with the atom(s) to which they are attached, form a 3 to 6-membered carbocyclic ring or a 3 to 6-membered heterocyclic ring each of which is independently substituted with 0 to 3 R 12 ; R 9 is selected from —CN, —C(O)OR 10 , —C(O)NR 11a R 11b —, —CO—NH—CO—R e , —CO—NH—SO 2 —R e , —CO—NH—SO—R e , —SO 2 —OH, —SO 2 —NH—CO—R e , —P(O)(OH) 2 , tetrazol-5-yl, —CH 2 —CO—NH—CO—R e , —CH 2 —CO—NH—SO 2 —R e , —CH 2 —CO—NH—SO—R e , —CH 2 —SO 2 —OH, —CH 2 —SO 2 —NH—CO—R e , —CH 2 —P(O)(OH) 2 , tetrazol-5-ylmethylene; R e is C 1-6 alkyl, C 3-6 cycloalkyl, haloalkyl, hydroxyalkyi, aminoalkyi, alkoxyalkyi, or haloalkoxyalkyi; R 10 is hydrogen or C 1-10 alkyl; and R 11a and R 11b are each independently hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, C 4-6 heterocyclyl, alkylamino, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxyalkyi, haloalkoxyalkyi, alkoxy, or haloalkoxy; and R 12 is halo, cyano, hydroxyl, amino, C 1-6 alkyl, alkylamino, haloalkyi, hydroxyalkyi, aminoalkyi, alkoxyalkyi, haloalkoxyalkyi, alkoxy, haloalkoxy, phenyl, or 5 to 6-membered heteroaryl. These compounds are selective LPA receptor inhibitors.